Date:11/15/2012

lescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contact:

Alliqua, Inc.
Steven Berger
646-218-1450 

 

'/>"/>

SOURCE Alliqua, Inc. Copyright©2012 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Daniels Sharpsmart Canada Awarded HealthPro Contract And Appoints Daniel Kennedy CEO Of Daniels Canada
2. Discovery Labs Appoints John R. Leone to Board of Directors
3. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
4. Cantel Medical Appoints Jorgen B. Hansen As Executive Vice President And Chief Operating Officer
5. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
6. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
7. Aushon BioSystems Appoints Bill Williams Vice President of Sales
8. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
9. Igenica Appoints Mary Haak-Frendscho, Ph.D., as Chief Executive Officer
10. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
11. Circassia Appoints Stewart Sharpe as Vice President Commercial Operations